TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用

摘要/Abstract

摘要：

经动脉化疗栓塞（TACE）是巴塞罗那临床肝癌（BCLC）分期系统B期肝细胞癌（HCC）的标准治疗方法。但TACE存在一定的局限性,TACE联合系统治疗或许更能使BCLC B/C期HCC患者获益。探索TACE分别联合靶向治疗、免疫治疗及靶向+免疫治疗BCLC B/C期HCC的疗效及安全性,将为HCC的临床治疗提供新的思路。

关键词:癌,肝细胞,化学栓塞,治疗性,分子靶向治疗,免疫疗法,综合疗法

Abstract:

Transcatheter arterial chemoembolization （TACE） is the standard treatment for Barcelona Clinic Liver Cancer （BCLC） stage B hepatocellular carcinoma （HCC）. However, TACE has some limitations, TACE combined with systemic therapy may be more beneficial to patients with BCLC stage B/C HCC. To explore the efficacy and safety of TACE combined with molecular targeted therapy, immunotherapy and molecular targeted therapy + immunotherapy in the treatment of B/C stage HCC of BCLC will provide new ideas for the clinical treatment of HCC.

Key words:Carcinoma, hepatocellular,Chemoembolization, therapeutic,Molecular targeted therapy,Immunotherapy,Combined modality therapy

宋佳, 胡钦勇. TACE联合靶向、免疫治疗在BCLC B/C期肝细胞癌中的应用[J]. 国际肿瘤学杂志, 2022, 49(9): 550-554.

Song Jia, Hu Qinyong. Application of TACE combined with molecular targeted therapy and immunotherapy in BCLC B/C hepatocellular carcinoma[J]. Journal of International Oncology, 2022, 49(9): 550-554.

参考文献38

[1]	Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012[J]. Int J Cancer, 2020, 147(2): 317-330. DOI: 10.1002/ijc.32723. doi:10.1002/ijc.32723pmid:31597196
[2]	Kudo M, Kawamura Y, Hasegawa K, et al. Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2021 update[J]. Liver Cancer, 2021, 10(3): 181-223. DOI: 10.1159/000514174. doi:10.1159/000514174pmid:34239808
[3]	European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69(1): 182-236. DOI: 10.1016/j.jhep.2018.03.019. doi:S0168-8278(18)30215-0pmid:29628281
[4]	Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160. DOI: 10.1200/JCO.21.00608. doi:10.1200/JCO.21.00608
[5]	Raoul JL, Forner A, Bolondi L, et al. Updated use of TACE for hepatocellular carcinoma treatment: how and when to use it based on clinical evidence[J]. Cancer Treat Rev, 2019, 72: 28-36. DOI: 10.1016/j.ctrv.2018.11.002. doi:10.1016/j.ctrv.2018.11.002
[6]	Adamek A, Kasprzak A. Insulin-like growth factor (IGF) system in liver diseases[J]. Int J Mol Sci, 2018, 19(5): 1308. DOI: 10.3390/ijms19051308. doi:10.3390/ijms19051308
[7]	Fan SKY, Li B, Chen Q, et al. Impact of interventional oncology therapies on tumor microenvironment and strategies to enhance their efficacy[J]. AJR Am J Roentgenol, 2018, 210(3): 648-656. DOI: 10.2214/AJR.16.17677. doi:10.2214/AJR.16.17677
[8]	李相成, 王宏伟, 李长贤. 肝癌综合治疗的现状与展望[J]. 中华消化外科杂志, 2018, 17(5): 433-436. DOI: 10.3760/cma.j.issn.1673-9752.2018.05.004. doi:10.3760/cma.j.issn.1673-9752.2018.05.004
[9]	Chang Y, Jeong SW, Young Jang J, et al. Recent updates of transarterial chemoembolilzation in hepatocellular carcinoma[J]. Int J Mol Sci, 2020, 21(21): 8165. DOI: 10.3390/ijms21218165. doi:10.3390/ijms21218165
[10]	Niu M, Yi M, Li N, et al. Advances of targeted therapy for hepatocellular carcinoma[J]. Front Oncol, 2021, 11: 719896. DOI: 10.3389/fonc.2021.719896. doi:10.3389/fonc.2021.719896
[11]	Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. DOI: 10.1038/s41572-020-00240-3. doi:10.1038/s41572-020-00240-3pmid:33479224
[12]	Lencioni R, Llovet JM, Han G, et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial[J]. J Hepatol, 2016, 64(5): 1090-1098. DOI: 10.1016/j.jhep.2016.01.012. doi:S0168-8278(16)00018-0pmid:26809111
[13]	Meyer T, Fox R, Ma YT, et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2017, 2(8): 565-575. DOI: 10.1016/S2468-1253(17)30156-5. doi:10.1016/S2468-1253(17)30156-5
[14]	Park JW, Kim YJ, Kim DY, et al. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase Ⅲ STAH trial[J]. J Hepatol, 2019, 70(4): 684-691. DOI: 10.1016/j.jhep.2018.11.029. doi:10.1016/j.jhep.2018.11.029
[15]	Kudo M, Ueshima K, Ikeda M, et al. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial[J]. Gut, 2020, 69(8): 1492-1501. DOI: 10.1136/gutjnl-2019-318934. doi:10.1136/gutjnl-2019-318934pmid:31801872
[16]	Wu FX, Chen J, Bai T, et al. The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma[J]. BMC Cancer, 2017, 17(1): 645. DOI: 10.1186/s12885-017-3545-5. doi:10.1186/s12885-017-3545-5
[17]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. doi:S0140-6736(18)30207-1pmid:29433850
[18]	Ando Y, Kawaoka T, Amioka K, et al. Efficacy and safety of lenvatinib-transcatheter arterial chemoembolization sequential therapy for patients with intermediate-stage hepatocellular carcinoma[J]. Oncology, 2021, 99(8): 507-517. DOI: 10.1159/000515865. doi:10.1159/000515865
[19]	Al-Salama ZT, Syed YY, Scott LJ. Lenvatinib: a review in hepatocellular carcinoma[J]. Drugs, 2019, 79(6): 665-674. DOI: 10.1007/s40265-019-01116-x. doi:10.1007/s40265-019-01116-xpmid:30993651
[20]	Kudo M. Lenvatinib may drastically change the treatment landscape of hepatocellular carcinoma[J]. Liver Cancer, 2018, 7(1): 1-19. DOI: 10.1159/000487148. doi:10.1159/000487148pmid:29662829
[21]	Fathi Maroufi N, Rashidi MR, Vahedian V, et al. Therapeutic potentials of apatinib in cancer treatment: possible mechanisms and clinical relevance[J]. Life Sci, 2020, 241: 117106. DOI: 10.1016/j.lfs.2019.117106. doi:10.1016/j.lfs.2019.117106
[22]	Chen S, Yu W, Zhang K, et al. Comparison of the efficacy and safety of transarterial chemoembolization with and without apatinib for the treatment of BCLC stage C hepatocellular carcinoma[J]. BMC Cancer, 2018, 18(1): 1131. DOI: 10.1186/s12885-018-5081-3. doi:10.1186/s12885-018-5081-3pmid:30453925
[23]	Yang Z, Chen G, Cui Y, et al. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study[J]. Cancer Biol Ther, 2019, 20(3): 321-327. DOI: 10.1080/15384047.2018.1529099. doi:10.1080/15384047.2018.1529099pmid:30332553
[24]	Kan X, Liang B, Zhou G, et al. Transarterial chemoembolization combined with apatinib for advanced hepatocellular carcinoma: a propensity score matching analysis[J]. Front Oncol, 2020, 10: 970. DOI: 10.3389/fonc.2020.00970. doi:10.3389/fonc.2020.00970pmid:32733791
[25]	Chiang CL, Chan SK, Lee SF, et al. First-line atezolizumab plus bevacizumab versus sorafenib in hepatocellular carcinoma: a cost-effectiveness analysis[J]. Cancers (Basel), 2021, 13(5): 931. DOI: 10.3390/cancers13050931. doi:10.3390/cancers13050931
[26]	Sangro B, Sarobe P, Hervás-Stubbs S, et al. Advances in immunotherapy for hepatocellular carcinoma[J]. Nat Rev Gastroenterol Hepatol, 2021, 18(8): 525-543. DOI: 10.1038/s41575-021-00438-0. doi:10.1038/s41575-021-00438-0pmid:33850328
[27]	Zongyi Y, Xiaowu L. Immunotherapy for hepatocellular carcinoma[J]. Cancer Lett, 2020, 470: 8-17. DOI: 10.1016/j.canlet.2019.12.002. doi:S0304-3835(19)30603-2pmid:31811905
[28]	Wu Y, Lin H, You X, et al. Immune checkpoint blockade in Chinese patients with hepatocellular carcinoma: characteristics and particularity[J]. Front Oncol, 2022, 12: 764923. DOI: 10.3389/fonc.2022.764923. doi:10.3389/fonc.2022.764923
[29]	Mikhail AS, Negussie AH, Mauda-Havakuk M, et al. Drug-eluting embolic microspheres: state-of-the-art and emerging clinical applications[J]. Expert Opin Drug Deliv, 2021, 18(3): 383-398. DOI: 10.1080/17425247.2021.1835858. doi:10.1080/17425247.2021.1835858pmid:33480306
[30]	Duffy AG, Ulahannan SV, Makorova-Rusher O, et al. Tremelimu-mab in combination with ablation in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3): 545-551. DOI: 10.1016/j.jhep.2016.10.029. doi:10.1016/j.jhep.2016.10.029
[31]	Pinato DJ, Cole T, Bengsch B, et al. A phase Ⅰb study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL[J]. Ann Oncol, 2019, 30(Supplement 5): v288. DOI: 10.1093/annonc/mdz247.076. doi:10.1093/annonc/mdz247.076
[32]	Greten TF, Mauda-Havakuk M, Heinrich B, et al. Combined locoregional-immunotherapy for liver cancer[J]. J Hepatol, 2019, 70(5): 999-1007. DOI: 10.1016/j.jhep.2019.01.027. doi:S0168-8278(19)30074-1pmid:30738077
[33]	Kloeckner R, Galle PR, Bruix J. Local and regional therapies for hepatocellular carcinoma[J]. Hepatology, 2021, 73(Suppl 1): 137-149. DOI: 10.1002/hep.31424. doi:10.1002/hep.31424
[34]	Sparchez Z, Radu P, Bartos A, et al. Combined treatments in hepatocellular carcinoma: time to put them in the guidelines?[J]. World J Gastrointest Oncol, 2021, 13(12): 1896-1918. DOI: 10.4251/wjgo.v13.i12.1896. doi:10.4251/wjgo.v13.i12.1896
[35]	Yang F, Xu GL, Huang JT, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response[J]. Front Immunol, 2022, 13: 847601. DOI: 10.3389/fimmu.2022.847601. doi:10.3389/fimmu.2022.847601
[36]	Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study[J]. J Hepatocell Carcinoma, 2021, 8: 1233-1240. DOI: 10.2147/JHC.S332420. doi:10.2147/JHC.S332420
[37]	Yang F, Xu GL, Huang JT, et al. Transarterial chemoembolization combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: efficacy and systemic immune response[J]. Front Immunol, 2022, 13: 847601. DOI: 10.3389/fimmu.2022.847601. doi:10.3389/fimmu.2022.847601
[38]	Llovet JM, Vogel A, Madoff DC, et al. Randomized phase 3 LEAP-012 study: transarterial chemoembolization with or without lenvatinib plus pembrolizumab for intermediate-stage hepatocellular carcinoma not amenable to curative treatment[J]. Cardiovasc Intervent Radiol, 2022, 45(4): 405-412. DOI: 10.1007/s00270-021-03031-9. doi:10.1007/s00270-021-03031-9pmid:35119481